Compounded Microdose Tirzepatide
US$ 22.74
glp-1 class diabetes drugs Another milestone in the evolution of GLP-1-based therapies GLP-1 Medications Infographic | Medidex
Description
Just three years later, in 2022, the game shifted again with tirzepatide (Mounjaro)
We do not know about our survey respondents BMI or health conditions, so it is not clear how far this reflects a genuine medical need or how often the drugs are used unnecessarily by people of a healthy weight
Modalities span checkpoint inhibitors, ADCs, CAR-T and targeted small molecules, with pipelines in protein degraders and bispecifics
It is about adding a fuller daily GLP-1 tracker and companion to the parts of the journey that feel scattered
